The US has exempted Indian pharmaceuticals from tariffs amidst President Trump’s broad tariff imposition, recognizing their ...

India's pharmaceutical sector avoids immediate impact from newly declared tariffs on over 60 countries. However, HDFC ...

Indian drugmaker stocks rose sharply after President Trump's latest tariff announcement left out pharmaceuticals, leading to a relief rally in the sector. Sun Pharmaceutical Industries rose 4.1% on ...

The Sensex and Nifty 50, are set to open substantially down on Thursday, following a sell-off in global markets in response ...

Shares of Indian drugmakers surged 5% on Thursday, in contrast to the drop in the broader stock market, after U.S. President ...

As trade tensions between India and the US escalate with President Trump’s latest tariff announcement, longstanding concerns ...

More than three dozen tech startups with a combined valuation of $100 billion are set to go public by 2027 in what would mark ...

India has emerged as a growing player in the illicit fentanyl trade, a new US intelligence report says, a designation likely ...

Ms Tyagi s now pursuing her master's degree. Divya Tyagi, an Indian-origin student in aerospace engineering at Pennsylvania State University, has made a groundbreaking achievement by reexamining a ...

At the time, Bangladesh was almost entirely reliant on imports for its pharmaceutical needs ... an API policy to incentivise local production, including a 100-percent tax exemption for companies that ...

Are pharmaceutical companies earning too much? Deciding whether pharmaceutical companies earn too much money is complicated. In this issue of JAMA, 2 reports take different approaches to the question.

Indian pharmaceutical companies are aggressively expanding their US presence through a wave of acquisitions, likely as a hedge against future uncertainties. Leading players like Sun Pharma ...